News & Media Press releases & statements Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 Category All categories Type - Statement - Press release Topic - Corporate and finance - Global health - Partnerships Research area - COVID-19 - Ebola - RSV - Seasonal influenza Uncategorized Keywords Apply filter Advanced Search Search Search Headlines Only Type All Statement Press release Topic All Corporate and finance Global health Partnerships Research area All COVID-19 Ebola RSV Seasonal influenza From To Asset Types Photos Video Audio Documents Events Standard Jun 5, 2023 Corporate and finance Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research Download May 9, 2023 Corporate and finance Novavax Reports First Quarter 2023 Financial Results and Operational Highlights Download May 2, 2023 Corporate and finance Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023 Download Mar 2, 2023 Corporate and finance Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) Download Feb 28, 2023 Corporate and finance Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights Download Feb 21, 2023 Corporate and finance Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023 Download Jan 25, 2023 Corporate and finance Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) Download Jan 9, 2023 Corporate and finance Novavax Names John C. Jacobs as New President & Chief Executive Officer Download Dec 28, 2022 Corporate and finance Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock Download Dec 15, 2022 Corporate and finance Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes Download Show 5102550100 per page«123456789…19»